 | • レポートコード：MRC2111A047 • 出版社/出版日：Transparency Market Research / 2021年8月16日 • レポート形態：英文、PDF、234ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Site Licence | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Enterprisewide | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の本調査資料では、CRS（慢性副鼻腔炎）急性憎悪治療の世界市場を広く調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、市場見通し、治療別（抗生物質、ロイコトリエン阻害剤、抗ヒスタミン剤、粘液溶解剤、充血除去剤）分析、投与経路別分析、流通チャネル別分析、感染タイプ別分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などの項目を掲載しています。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・市場見通し ・CRS（慢性副鼻腔炎）急性憎悪治療の世界市場規模：治療別（抗生物質、ロイコトリエン阻害剤、抗ヒスタミン剤、粘液溶解剤、充血除去剤） ・CRS（慢性副鼻腔炎）急性憎悪治療の世界市場規模：投与経路別 ・CRS（慢性副鼻腔炎）急性憎悪治療の世界市場規模：流通チャネル別 ・CRS（慢性副鼻腔炎）急性憎悪治療の世界市場規模：感染タイプ別 ・CRS（慢性副鼻腔炎）急性憎悪治療の世界市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ） ・競争状況 |
Acute Exacerbation of CRS Treatment Market – Scope of Report
TMR’s report on the global acute exacerbation of CRS treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of these indicators for the market during the forecast period from 2021 to 2031. The report provides the revenue of the global acute exacerbation of CRS treatment market for the period 2017–2031, considering 2020 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global acute exacerbation of CRS treatment market from 2021 to 2031.
The report has been prepared after extensive research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global acute exacerbation of CRS treatment market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various attributes of the global acute exacerbation of CRS treatment market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Moreover, the report sheds light on changing competitive dynamics in the global acute exacerbation of CRS treatment market. These serve as valuable tools for existing market players as well as entities interested in participating in the global acute exacerbation of CRS treatment market.
The report also delves into the competitive landscape of the global acute exacerbation of CRS treatment market. Key players operating in the global acute exacerbation of CRS treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global acute exacerbation of CRS treatment market that have been profiled in this report.
Key Questions Answered in Acute Exacerbation of CRS Treatment Report
What is the sales/revenue generated by acute exacerbation of CRS treatment products across all regions during the forecast period?
What are the opportunities in the global acute exacerbation of CRS treatment market?
What are major drivers, restraints, opportunities, and threats in the global market?
Which region is set to expand at the fastest CAGR during the forecast period?
Which treatment segment is expected to generate the highest revenue globally in 2031? Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Acute Exacerbation of CRS Treatment Market – Research Objectives and Research Approach
The comprehensive report on the global acute exacerbation of CRS treatment market begins with an overview, followed by the scope and objectives of the study. Following this, the report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of treatments.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that have been appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global acute exacerbation of CRS treatment market in terms of treatment, route of administration, distribution channel, infection type, and region. Key segments under each criteria have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders to make informed business decisions for investment in the global acute exacerbation of CRS treatment market.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Acute Exacerbation of CRS Treatment Market
4. Market Overview
4.1. Introduction & Overview
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Global Acute Exacerbation of CRS Treatment Market Analysis and Forecast, 2017–2031
5. Market Outlook
5.1. Clinical Trials & Regulatory Approvals Analysis
5.2. List of Brand / Product Approved
5.3. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)
5.4. Technological Advancements
5.5. Disease Prevalence & Incidence
6. Global Acute Exacerbation of CRS Treatment Market Analysis and Forecast, by Treatment
6.1. Introduction & Definition
6.2. Global Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
6.2.1. Acute Exacerbation of CRS
6.2.1.1. Antibiotics
6.2.1.2. Leukotriene Inhibitors
6.2.1.3. Antihistamines
6.2.1.4. Mucolytics
6.2.1.5. Decongestants
6.2.1.6. Nasal Saline Irrigation
6.2.1.7. Oral Corticosteroids
6.2.1.8. Endoscopic sinus surgery
6.2.1.9. Others
6.3. Global Acute Exacerbation of CRS Treatment Market Attractiveness Analysis, by Route of Administration
7. Global Acute Exacerbation of CRS Treatment Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Global Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Route of Administration2017–2031
7.2.1. Acute Exacerbation of CRS
7.2.1.1. Topical
7.2.1.2. Nasal
7.2.1.3. Oral
7.2.1.4. Injectable
7.3. Global Acute Exacerbation of CRS Treatment Market Attractiveness Analysis, by Route of Administration
8. Global Acute Exacerbation of CRS Treatment Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Global Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
8.2.1. Acute Exacerbation of CRS
8.2.1.1. Online Pharmacies
8.2.1.2. Retail Pharmacies
8.2.1.3. Hospital Pharmacies
8.3. Global Acute Exacerbation of CRS Treatment Market Attractiveness Analysis, by Distribution Channel
9. Global Acute Exacerbation of CRS Treatment Market Analysis and Forecast, by Infection Type
9.1. Introduction & Definition
9.2. Global Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031
9.2.1. Acute Exacerbation of CRS
9.2.1.1. Staphylococcus Species
9.2.1.2. Others
9.3. Global Acute Exacerbation of CRS Treatment Market Attractiveness Analysis, by Infection Type
10. Global Acute Exacerbation of CRS Treatment Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Global Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Global Acute Exacerbation of CRS Treatment Market Attractiveness Analysis, by Region
11. North America Acute Exacerbation of CRS Treatment Market Analysis and Forecast
11.1. Introduction
11.2. North America Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
11.2.1. Acute Exacerbation of CRS
11.2.1.1. Antibiotics
11.2.1.2. Leukotriene Inhibitors
11.2.1.3. Antihistamines
11.2.1.4. Mucolytics
11.2.1.5. Decongestants
11.2.1.6. Nasal Saline Irrigation
11.2.1.7. Oral Corticosteroids
11.2.1.8. Endoscopic sinus surgery
11.2.1.9. Others
11.3. North America Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
11.3.1. Acute Exacerbation of CRS
11.3.1.1. Topical
11.3.1.2. Nasal
11.3.1.3. Oral
11.3.1.4. Injectable
11.4. North America Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
11.4.1. Acute Exacerbation of CRS
11.4.1.1. Online Pharmacies
11.4.1.2. Retail Pharmacies
11.4.1.3. Hospital Pharmacies
11.5. North America Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031
11.5.1. Acute Exacerbation of CRS
11.5.1.1. Staphylococcus Species
11.5.1.2. Others
11.6. North America Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031
11.6.1. U.S.
11.6.2. Canada
11.7. North America Acute Exacerbation of CRS Treatment Market Attractiveness Analysis
11.7.1. By Treatment
11.7.2. By Route of Administration
11.7.3. By Distribution Channel
11.7.4. Infection Type
11.7.5. By Country
12. Europe Acute Exacerbation of CRS Treatment Market Analysis and Forecast
12.1. Introduction
12.2. Europe Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
12.2.1. Acute Exacerbation of CRS
12.2.1.1. Antibiotics
12.2.1.2. Leukotriene Inhibitors
12.2.1.3. Antihistamines
12.2.1.4. Mucolytics
12.2.1.5. Decongestants
12.2.1.6. Nasal Saline Irrigation
12.2.1.7. Oral Corticosteroids
12.2.1.8. Endoscopic sinus surgery
12.2.1.9. Others
12.3. Europe Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
12.3.1. Acute Exacerbation of CRS
12.3.1.1. Topical
12.3.1.2. Nasal
12.3.1.3. Oral
12.3.1.4. Injectable
12.4. Europe Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
12.4.1. Acute Exacerbation of CRS
12.4.1.1. Staphylococcus Species
12.4.1.2. Others
12.5. Europe Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
12.5.1. Germany
12.5.2. U.K.
12.5.3. France
12.5.4. Spain
12.5.5. Italy
12.5.6. Rest of Europe
12.6. Europe Acute Exacerbation of CRS Treatment Market Attractiveness Analysis
12.6.1. By Treatment
12.6.2. By Route of Administration
12.6.3. By Distribution Channel
12.6.4. By Infection Type
12.6.5. By Country/Sub-region
13. Asia Pacific Acute Exacerbation of CRS Treatment Market Analysis and Forecast
13.1. Introduction
13.2. Asia Pacific Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
13.2.1. Acute Exacerbation of CRS
13.2.1.1. Antibiotics
13.2.1.2. Leukotriene Inhibitors
13.2.1.3. Antihistamines
13.2.1.4. Mucolytics
13.2.1.5. Decongestants
13.2.1.6. Nasal Saline Irrigation
13.2.1.7. Oral Corticosteroids
13.2.1.8. Endoscopic sinus surgery
13.2.1.9. Others
13.3. Asia Pacific Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
13.3.1. Acute Exacerbation of CRS
13.3.1.1. Topical
13.3.1.2. Nasal
13.3.1.3. Oral
13.3.1.4. Injectable
13.4. Asia Pacific Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
13.4.1. Acute Exacerbation of CRS
13.4.1.1. Online Pharmacies
13.4.1.2. Retail Pharmacies
13.4.1.3. Hospital Pharmacies
13.5. Asia Pacific Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
13.5.1. China
13.5.2. Japan
13.5.3. India
13.5.4. Australia & New Zealand
13.5.5. Rest of Asia Pacific
13.6. Asia Pacific Acute Exacerbation of CRS Treatment Market Attractiveness Analysis
13.6.1. By Treatment
13.6.2. By Route of Administration
13.6.3. By Distribution Channel
13.6.4. Infection Type
13.6.5. By Country/Sub-region
14. Latin America Acute Exacerbation of CRS Treatment Market Analysis and Forecast
14.1. Introduction
14.2. Latin America Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
14.2.1. Acute Exacerbation of CRS
14.2.1.1. Antibiotics
14.2.1.2. Leukotriene Inhibitors
14.2.1.3. Antihistamines
14.2.1.4. Mucolytics
14.2.1.5. Decongestants
14.2.1.6. Nasal Saline Irrigation
14.2.1.7. Oral Corticosteroids
14.2.1.8. Endoscopic sinus surgery
14.2.1.9. Others
14.3. Latin America Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
14.3.1. Acute Exacerbation of CRS
14.3.1.1. Topical
14.3.1.2. Nasal
14.3.1.3. Oral
14.3.1.4. Injectable
14.4. Latin America Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
14.4.1. Acute Exacerbation of CRS
14.4.1.1. Online Pharmacies
14.4.1.2. Retail Pharmacies
14.4.1.3. Hospital Pharmacies
14.5. Latin America Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
14.5.1. Brazil
14.5.2. Mexico
14.5.3. Rest of Latin America
14.6. Latin America Acute Exacerbation of CRS Treatment Market Attractiveness Analysis
14.6.1. By Treatment
14.6.2. By Route of Administration
14.6.3. By Distribution Channel
14.6.4. Infection Type
14.6.5. By Country/Sub-region
15. Middle East & Africa Acute Exacerbation of CRS Treatment Market Analysis and Forecast
15.1. Introduction
15.2. Middle East & Africa Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
15.2.1. Acute Exacerbation of CRS
15.2.1.1. Antibiotics
15.2.1.2. Leukotriene Inhibitors
15.2.1.3. Antihistamines
15.2.1.4. Mucolytics
15.2.1.5. Decongestants
15.2.1.6. Nasal Saline Irrigation
15.2.1.7. Oral Corticosteroids
15.2.1.8. Endoscopic sinus surgery
15.2.1.9. Others
15.3. Middle East & Africa Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
15.3.1. Acute Exacerbation of CRS
15.3.1.1. Topical
15.3.1.2. Nasal
15.3.1.3. Oral
15.3.1.4. Injectable
15.4. Middle East & Africa Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
15.4.1. Acute Exacerbation of CRS
15.4.1.1. Online Pharmacies
15.4.1.2. Retail Pharmacies
15.4.1.3. Hospital Pharmacies
15.5. Middle East & Africa Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031
15.5.1. Acute Exacerbation of CRS
15.5.1.1. Staphylococcus Species
15.5.1.2. Others
15.6. Middle East & Africa Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Middle East & Africa Acute Exacerbation of CRS Treatment Market Attractiveness Analysis
15.7.1. By Treatment
15.7.2. By Route of Administration
15.7.3. By Distribution Channel
15.7.4. By Infection Type
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Position Analysis, by Company, 2020
16.2. Company Profiles
16.2.1. Sun Pharmaceutical Industries, Inc.
16.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.1.2. Growth Strategies
16.2.1.3. SWOT Analysis
16.2.2. Pfizer Inc.
16.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.2.2. Growth Strategies
16.2.2.3. SWOT Analysis
16.2.3. Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
16.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.3.2. Growth Strategies
16.2.3.3. SWOT Analysis
16.2.4. Fresenius Kabi USA, LLC.
16.2.4.1. Company Overview (HQ, Business Segments)
16.2.4.2. Growth Strategies
16.2.4.3. SWOT Analysis
16.2.5. Dr. Reddy’s Laboratories, Inc.
16.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.5.2. Growth Strategies
16.2.5.3. SWOT Analysis
16.2.6. Novartis AG
16.2.6.1. Company Overview (HQ, Business Segments)
16.2.6.2. Growth Strategies
16.2.6.3. SWOT Analysis
16.2.7. Teva Pharmaceutical Industries Ltd
16.2.7.1. Company Overview (HQ, Business Segments)
16.2.7.2. Growth Strategies
16.2.7.3. SWOT Analysis
16.2.8. Sanofi
16.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.8.2. Growth Strategies
16.2.8.3. SWOT Analysis
16.2.9. Abbott Laboratories
16.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.9.2. Growth Strategies
16.2.9.3. SWOT Analysis
16.2.10. Bayer AG
16.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.10.2. Growth Strategies
16.2.10.3. SWOT Analysis
16.2.11. Eli Lilly And Company
16.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.11.2. Growth Strategies
16.2.11.3. SWOT Analysis
16.2.12. Bristol-Myers Squibb
16.2.12.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.12.2. Growth Strategies
16.2.12.3. SWOT Analysis
16.2.13. Merck & Co, Inc.
16.2.13.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.13.2. Growth Strategies
16.2.13.3. SWOT Analysis
16.2.14. AstraZeneca Plc
16.2.14.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.14.2. Growth Strategies
16.2.14.3. SWOT Analysis
16.2.15. Amneal Pharmaceuticals LLC
16.2.15.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.15.2. Growth Strategies
16.2.15.3. SWOT Analysis
16.2.16. GlaxoSmithKline plc.
16.2.16.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.16.2. Growth Strategies
16.2.16.3. SWOT Analysis
16.2.17. Aurobindo Pharma
16.2.17.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.17.2. Growth Strategies
16.2.17.3. SWOT Analysis
16.2.18. Hikma Pharmaceuticals plc
16.2.18.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.18.2. Growth Strategies
16.2.18.3. SWOT Analysis
16.2.19. Wockhardt
16.2.19.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.19.2. Growth Strategies
16.2.19.3. SWOT Analysis
16.2.20. Mylan N.V.
16.2.20.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.20.2. Growth Strategies
16.2.20.3. SWOT Analysis
Table 01: Global Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 02: Global Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2031
Table 03: Global Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 04: Global Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 05: Global Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031
Table 06: Global Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 07: North America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 08: North America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 09: North America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2031
Table 10: North America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 11: North America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 12: North America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031
Table 13: Europe Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Europe Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 15: Europe Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2031
Table 16: Europe Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 17: Europe Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 18: Europe Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031
Table 19: Asia Pacific Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 20: Asia Pacific Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 21: Asia Pacific Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2031
Table 22: Asia Pacific Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 23: Asia Pacific Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 24: Asia Pacific Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031
Table 25: Latin America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 26: Latin America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 27: Latin America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2031
Table 28: Latin America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 29: Latin America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 30: Latin America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031
Table 31: Middle East & Africa Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 32: Middle East & Africa Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 33: Middle East & Africa Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2031
Table 34: Middle East & Africa Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 35: Middle East & Africa Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 36: Middle East & Africa Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031